In modern neuro-oncology, genetic and molecular testing has become indispensable for accurately diagnosing brain tumors and tailoring treatment strategies. According to Dr. Simon Khagi of Hoag Hospital – Newport Beach, “Understanding a tumor’s genetic profile is the first step toward offering truly personalized care to our patients.”
What Is Genetic and Molecular Testing? Genetic and molecular testing refers to laboratory techniques that analyze DNA changes, gene expression patterns, and specific biomarkers within tumor cells. Clinicians commonly use methods such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR) to uncover these alterations. Tissue for testing is typically collected during a biopsy or surgical resection and processed by a pathologist before in-depth molecular analysis begins. “Our ability to sequence tumor DNA has revolutionized how we classify and approach brain cancers,” notes Dr. Khagi.
Why Testing Matters in Brain Tumors The clinical behavior of brain tumors can vary dramatically based on their molecular characteristics. For instance, tumors harboring an IDH mutation tend to have a better prognosis than their IDH wildtype counterparts, which often exhibit more aggressive growth. Identifying these mutations not only refines diagnosis but also guides eligibility for clinical trials and potential targeted therapies. Dr. Khagi explains, “When a patient’s tumor is IDH wildtype, we immediately know which trials and regimens are most appropriate, helping us avoid ineffective treatments.”
How It Influences Treatment Genetic and molecular findings directly inform therapeutic decisions. Results can dictate whether a patient should receive standard chemotherapy, radiation, targeted agents, or be enrolled in a precision medicine trial. In many glioblastoma studies, only patients with certain molecular profiles—such as IDH wildtype—are eligible, ensuring that experimental therapies are tested in the most relevant populations. “Testing spares patients the toxicity of treatments unlikely to work and points us toward the most promising options,” says Dr. Khagi.
Timing of Testing Testing is routinely performed soon after tumor sampling. Following an initial pathology review, specimens are sent for comprehensive genetic analysis. If a tumor recurs, re-biopsy and re-testing are also standard practice to detect emerging mutations that could open new treatment avenues. As Dr. Khagi remarks, “Tumors evolve, and retesting can uncover novel targets that weren’t present at diagnosis.”
Challenges and Limitations Despite its promise, molecular testing has hurdles. Many genetic alterations detected may not yet be “actionable”—that is, there may be no existing drug to target them. Insurance coverage and access to specialized testing centers can also delay results. Occasionally, specimens may not have enough viable tissue for analysis, requiring repeat procedures. Dr. Khagi emphasizes, “While we’re mapping more alterations than ever, translating those findings into effective treatments remains a work in progress.”
Genetic and molecular testing stands at the forefront of personalized neuro-oncology, offering insights that refine diagnoses and guide therapy. As technology and our understanding of tumor biology advance, these tools will continue to expand treatment options and improve outcomes for patients facing brain tumors.
References
- Khagi S., Hoag Hospital – Newport Beach – expert commentary and quotes provided